Although gonadotropinomas have been shown to express SSTR (mainly SSTR2 and SSTR5) and type 2 dopamine receptors (DR2), the results with SSAs and dopamine agonists (DAs) are discrete regarding tumor shrinkage [67]. Here, SSTR5 is linked to neoplasm.